Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
INWK
2576
DELISTED
InnerWorkings, Inc.
INWK
| $1.12M | ﹤0.01% |
203,600
+84,900
| +72% | +$411K |
|
2577
Vanguard Morningstar Mid-Cap Value ETF
VOE
$24.6B
| $1.12M | ﹤0.01% |
9,400
+4,800
| +104% | +$553K |
|
|
SPRT
2578
DELISTED
support.com, Inc.
SPRT
| $1.12M | ﹤0.01% |
1,026,536
| – | – |
|
|
ADMS
2579
DELISTED
Adamas Pharmaceuticals
ADMS
| $1.11M | ﹤0.01% |
292,780
+169,145
| +137% | +$810K |
|
2580
iShares MSCI Australia ETF
EWA
$1.44B
| $1.11M | ﹤0.01% |
49,000
+19,400
| +66% | +$437K |
|
2581
Vanguard Morningstar Large-Cap ETF
VV
$54.7B
| $1.11M | ﹤0.01% |
+7,500
| New | +$1.06M |
|
|
SGMA
2582
DELISTED
Sigmatron International
SGMA
| $1.1M | ﹤0.01% |
272,928
+5,538
| +2% | +$23.4K |
|
2583
Innodata
INOD
$2.11B
| $1.1M | ﹤0.01% |
963,153
+20,600
| +2% | +$26.3K |
|
2584
State Street SPDR Bloomberg Emerging Markets Local Bond ETF
EBND
$2.28B
| $1.09M | ﹤0.01% |
39,227
+29,368
| +298% | +$807K |
|
2585
BioXcel Therapeutics
BTAI
$37.4M
| $1.09M | ﹤0.01% |
4,681
-175
| -4% | -$17.6K |
|
2586
Prothena Corp
PRTA
$458M
| $1.09M | ﹤0.01% |
69,100
+24,100
| +54% | +$258K |
|
|
SOL
2587
DELISTED
Emeren Group
SOL
| $1.09M | ﹤0.01% |
772,442
-6,409
| -0.8% | -$9.52K |
|
2588
iShares Core Moderate Allocation ETF
AOM
$1.78B
| $1.09M | ﹤0.01% |
27,163
+16,063
| +145% | +$636K |
|
2589
Schwab US Aggregate Bond ETF
SCHZ
$10.5B
| $1.08M | ﹤0.01% |
40,356
+16,756
| +71% | +$449K |
|
2590
Pluri
PLUR
$18.5M
| $1.08M | ﹤0.01% |
34,177
+10,898
| +47% | +$312K |
|
2591
Tenet Healthcare
THC
$21.5B
| $1.07M | ﹤0.01% |
28,275
-16,800
| -37% | -$503K |
|
2592
Vanguard Long-Term Corporate Bond ETF
VCLT
$8.73B
| $1.07M | ﹤0.01% |
10,600
+1,600
| +18% | +$161K |
|
2593
Pure Cycle
PCYO
$271M
| $1.07M | ﹤0.01% |
85,200
-9,792
| -10% | -$115K |
|
|
PSB
2594
DELISTED
PS Business Parks, Inc.
PSB
| $1.07M | ﹤0.01% |
6,500
+1,088
| +20% | +$191K |
|
2595
Cannae Holdings
CNNE
$654M
| $1.07M | ﹤0.01% |
28,801
-145,999
| -84% | -$4.8M |
|
2596
Security National Financial
SNFCA
$242M
| $1.07M | ﹤0.01% |
263,761
+24,673
| +10% | +$89.9K |
|
|
ALLK
2597
DELISTED
Allakos
ALLK
| $1.07M | ﹤0.01% |
11,200
-151,500
| -93% | -$13.3M |
|
|
RYZ
2598
Ryerson Holding Corp
RYZ
$1.5B
| $1.07M | ﹤0.01% |
+90,200
| New | +$891K |
|
|
RBCN
2599
DELISTED
Rubicon Technology, Inc.
RBCN
| $1.07M | ﹤0.01% |
128,104
+2,900
| +2% | +$24.5K |
|
2600
Linde
LIN
$222B
| $1.06M | ﹤0.01% |
5,000
-173,800
| -97% | -$35M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.